[Corrections] Correction to Lancet Oncol 2014; 15: 1503–12

Leggi l'articolo originale

Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol 2014; 15: 1503–12—In the eighth paragraph of the Results section of this Article, the first sentence should have been “Overall responses were noted in 59 (92%, 95% CI 83–97) of 64 patients (table 5)”. This correction has been made to the online version as of July 1, 2019.

Lascia un commento